Tiziana Life Sciences (TLSA, Financial) has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City for its Phase 2 clinical trial. The study, which focuses on evaluating the intranasal delivery of foralumab for individuals with non-active Secondary Progressive Multiple Sclerosis (na-SPMS), now includes this fifth location in addition to existing sites at Yale University (Trades, Portfolio), Johns Hopkins University, Brigham and Women’s Hospital, and the University of Massachusetts.
The primary aim of the trial is to assess the safety and effectiveness of Tiziana's innovative treatment for multiple sclerosis, a long-term autoimmune condition impacting the central nervous system. Building on earlier preclinical and clinical insights, the Phase 2 trial is structured to transition into an open-label extension phase after the blinded phase. In this extension, all participants, including those initially on placebo, will receive intranasal foralumab over six months, allowing researchers to gather data on its long-term safety and benefits for the na-SPMS population.
Also check out:
